Armistice Capital LLC Acquires New Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Armistice Capital LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 500,000 shares of the company’s stock, valued at approximately $18,710,000.

Other large investors have also recently added to or reduced their stakes in the company. Amundi raised its position in shares of Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after purchasing an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after buying an additional 984 shares during the period. Empowered Funds LLC acquired a new position in Harmony Biosciences in the 1st quarter valued at $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Harmony Biosciences by 53.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after acquiring an additional 33,058 shares during the period. Finally, Cetera Investment Advisers lifted its position in Harmony Biosciences by 9.8% during the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock worth $266,000 after acquiring an additional 748 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Analysts Set New Price Targets

HRMY has been the topic of several research analyst reports. Weiss Ratings downgraded Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Truist Financial increased their target price on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a research report on Monday, February 23rd. Finally, UBS Group cut their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Harmony Biosciences has an average rating of “Hold” and a consensus target price of $40.89.

Harmony Biosciences Trading Down 0.2%

Shares of HRMY opened at $33.77 on Thursday. The stock’s 50-day moving average price is $31.23 and its 200 day moving average price is $33.09. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 13.62, a P/E/G ratio of 0.24 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The firm had revenue of $215.39 million during the quarter, compared to the consensus estimate of $220.84 million. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.Harmony Biosciences’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 EPS. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.